NCT04407182View on ClinicalTrials.gov

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 4, 2020

Primary Completion Date

August 1, 2020

Study Completion Date

October 1, 2020

Conditions
Covid-19Sars-CoV2Diabete MellitusCardiopathyPulmonary DiseaseRenal DiseaseLiver Diseases
Interventions
DIETARY_SUPPLEMENT

Viusid and Asbrip

"Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.~Treatment duration: 21 days."

Trial Locations (1)

090510

Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT04407182 - Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19 | Biotech Hunter | Biotech Hunter